GKOS or ISRG or NTRA

Key Takeaways

• Glaukos Corporation (GKOS) has surged roughly 39% year-to-date, driven by the successful launch of Epioxa, a first-of-its-kind FDA-approved topical treatment for keratoconus, and a raised 2026 revenue outlook.
• Intuitive Surgical (ISRG) has declined approximately 39% year-to-date and recently fell sharply after maintaining its procedure-growth guidance, raising concerns about moderating U.S. surgical volumes and competitive pressures.
• Natera (NTRA) has rallied nearly 90% over the past twelve months and over 450% across three years, reflecting robust demand for its molecular diagnostics and genetic testing platforms, though the company remains unprofitable on a trailing basis.
• All three stocks operate in high-growth healthcare segments but exhibit starkly different market capitalizations, profitability profiles, and risk-reward dynamics.
• Recent divergence in price momentum — with GKOS and NTRA trending higher while ISRG faces a pronounced correction — underscores the importance of evaluating trend consistency alongside fundamentals.

Introduction

Investors scanning the healthcare and medical technology landscape increasingly encounter three distinctive names: Glaukos Corporation, Intuitive Surgical, and Natera. Each occupies a specialized niche — ophthalmic devices, robotic-assisted surgery, and molecular diagnostics, respectively — yet all three are united by their reliance on innovation-led growth and expanding addressable markets. This stock comparison evaluates how GKOS, ISRG, and NTRA stack up across recent performance, business fundamentals, and market sentiment. For traders weighing relative performance and market positioning within healthcare, understanding the trade-offs among these three names is especially relevant in the current environment, where momentum, valuation sensitivity, and sector rotation are shaping capital flows.

GKOS Overview and Recent Performance

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that develops therapies for glaucoma, corneal disorders, and retinal diseases. Its flagship products include the iStent family of micro-invasive glaucoma surgery (MIGS) devices, which are designed to reduce intraocular pressure by restoring natural aqueous humor outflow pathways. In recent weeks, GKOS has exhibited strong upward momentum, gaining approximately 23% over the past month and surpassing $156 per share — near its 52-week high. A major catalyst has been the March 2026 launch of Epioxa, the first and only FDA-approved incision-free topical treatment for keratoconus, a rare sight-threatening corneal disease. The company also raised its full-year 2026 sales guidance in April following stronger-than-expected business performance. With trailing twelve-month revenue of roughly $551 million, up more than 36% year-over-year, and a market capitalization near $9.2 billion, Glaukos remains unprofitable on a net income basis, reporting a negative EPS (earnings per share) of approximately -$3.29. However, analysts remain broadly constructive, with a consensus "Strong Buy" rating and an average price target around $165, reflecting optimism about the company's pipeline and commercial execution.

ISRG Overview and Recent Performance

Intuitive Surgical is the dominant player in robotic-assisted minimally invasive surgery, best known for its da Vinci surgical systems. As of mid-2026, the company had an installed base of over 11,700 da Vinci systems worldwide. Despite delivering second-quarter 2026 revenue of $2.89 billion — a 19% year-over-year increase that beat analyst expectations — ISRG stock has experienced a pronounced selloff. Shares have declined roughly 39% year-to-date and recently fell approximately 15% in a single week following the earnings report. The primary concern: the company maintained its full-year da Vinci procedure-growth guidance of 13.5% to 15.5%, which would represent the slowest expansion in several years, and management noted that U.S. surgical volumes showed signs of moderation. The expiration of ACA (Affordable Care Act) subsidies was cited as a mild headwind affecting patient decision-making around elective procedures. Competitive dynamics are also in focus, with Medtronic expanding its Hugo robotic system and Stryker introducing a new Mako platform for knee replacements. ISRG remains solidly profitable, with trailing EPS of $8.70 and a P/E (price-to-earnings) ratio near 39.6, but the sharp technical breakdown below its 200-week moving average has unsettled momentum-oriented investors. The company's market capitalization stands at approximately $122 billion, making it the largest of the three names by a wide margin.

NTRA Overview and Recent Performance

Natera is a molecular diagnostics company specializing in cell-free DNA testing across women's health, oncology, and organ health. Its non-invasive tests — including Panorama for prenatal screening and Signatera for cancer monitoring — have driven rapid revenue growth. Over the past twelve months, NTRA has returned nearly 90%, and its three-year return exceeds 450%, reflecting strong commercial adoption and expanding test volumes. In recent weeks, the stock has continued to trade near its 52-week high of approximately $288, gaining around 20% over the past month. Trailing twelve-month revenue reached roughly $2.3 billion, representing 36% year-over-year growth. Despite this momentum, Natera remains unprofitable, with a trailing EPS of -$1.62 and an enterprise value-to-EBITDA (earnings before interest, taxes, depreciation, and amortization) ratio in negative territory. The company's market capitalization has grown to approximately $39 billion, and institutional ownership exceeds 95%, indicating strong professional conviction. With a beta of 1.50, NTRA carries higher volatility than the broader market but has rewarded investors who positioned for its sustained diagnostic-testing tailwind. Its forward trajectory hinges on continued reimbursement wins, test menu expansion, and progress toward profitability.

Trending AI Robots

In an environment where three healthcare stocks can move in sharply different directions, many traders turn to systematic tools for navigating such divergence. Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots, filtered from hundreds of available strategies that collectively trade thousands of different tickers. Only those bots demonstrating the strongest alignment with current market conditions earn a place in this featured section. The bots span a wide range of trading styles — from short-term momentum strategies to swing trading and longer-term trend-following approaches — each with distinct performance statistics, timeframes, and ticker coverage. This diversity allows traders to assess which automated strategies are resonating with real-time market dynamics. For those seeking a data-driven edge in stock selection and timing, the Trending AI Robots page offers a practical starting point to explore what AI-driven analysis reveals in the current market landscape.

Head-to-Head Comparison

The contrast among these three stocks is striking. GKOS and NTRA are both unprofitable, high-growth companies with strong recent price momentum and positive catalysts — Epioxa for Glaukos and expanding test adoption for Natera. ISRG, by contrast, is a profitable mega-cap giant with far greater revenue scale but currently faces a growth-moderation narrative that has triggered a significant repricing. In terms of valuation sensitivity, ISRG trades at a trailing P/E of roughly 39.6, while GKOS and NTRA lack positive P/E ratios entirely, making them more reliant on revenue multiples and future earnings expectations. Risk factors also diverge: ISRG contends with mounting robotic-surgery competition and U.S. utilization headwinds; GKOS must execute on Epioxa's commercial ramp and advance its clinical pipeline; NTRA faces reimbursement uncertainty and the challenge of eventually converting rapid revenue growth into sustainable profitability. From a sector-exposure standpoint, all three are healthcare names, but their end markets — ophthalmology, robotic surgery, and genetic diagnostics — have distinct demand drivers and regulatory landscapes. Market sentiment currently favors GKOS and NTRA, both trading near highs, while ISRG navigates a sharp correction that has tested long-term technical support levels.

Tickeron AI Verdict

Based on observable factors such as trend consistency, catalyst visibility, and relative market positioning, Tickeron's AI-driven analysis would likely view GKOS and NTRA more favorably than ISRG in the current environment. Both GKOS and NTRA exhibit strong upward trend structures, positive revenue momentum, and fresh catalysts that have translated into sustained buying interest. NTRA's multi-year trend is particularly impressive, though its elevated valuation and lack of profitability introduce a higher sensitivity to any disappointment. ISRG, while fundamentally robust, contends with decelerating procedure growth, increasing competition, and a technical breakdown below key moving averages — factors that trend-following algorithms typically penalize. Among the three, GKOS currently presents the most balanced combination of recent price momentum, a concrete new product catalyst in Epioxa, and a manageable market capitalization that leaves room for upside if commercial execution continues to outperform expectations. As always, AI-based assessments reflect probabilities derived from historical patterns and real-time data rather than certainties, and no single factor should be considered in isolation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations